RE:RE:RE:RE:posted this on nov. 4, now we know what was fishywhy buy now.. in order to run its Phase III in Panc, the cost has just risen from 30 million to 80 million... ONCY has 40 million in cash... so, without a partner, who will be paying for this additional 50 million...
Buying now, in the HOPE that a partner will pay for this trial is very risky... and raising money in this market is likely to be massively dilutive. A potential partner such as Roche can just sit back and twiddle their thumbs, while the valuation of ONCY falls through the floor... and offer terms to their advantage when making any offer.
Remember, ONCY needs an approval by 2027, lest it's patent expire. Perhaps Adlai Nortye, who first signed up 5 years ago, can begin their Phase III.
so go ahead, load up the truck.. but you'll probably get it cheaper next month..!